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Abstract  
Context: The optimal management for screen-detected localised prostate cancer remains controversial, 
related to over-treatment issues of screening and the non-randomised evidence base. Active Surveillance 
(AS) aims to delay or avoid curative therapy but may potentially harm patients' well-being through living 
with untreated prostate cancer. 
Objective: To systematically review the literature on quality of life (QoL) in AS patients.  
Evidence acquisition: Embase, Medline, Psychinfo, Cochrane Central, Web of Science and PubMed 
databases were searched in May 2014 using quality of life (QoL), active surveillance, prostate cancer, their 
synonyms and targeted manual searches. The psychological dimensions related to HRQoL outcomes were 
anxiety and depression, distress, decisional conflict and mental health.  
Evidence synthesis: Ten clinical and research-based AS studies worldwide measured HRQoL and related 
psychological facets in 6 cross-sectional studies and 4 cohorts (follow-up: 9-36 months, published: 2006-
2014). Six studies were linked to published AS cohorts. In total, 966 AS men (mean 102/study) were 
assessed (mean age 66 years). AS patients had good overall HRQoL scores which were comparable or better 
than those of patients undergoing or post-radical treatment (comparator group in four studies), men’s 
partners (one) and population-based data (three). Anxiety and depression scores were favourable. Selection 
bias may be present as none were randomised comparisons. Decreased psychological well-being may be 
partly predicted by AS patients’ baseline and clinical characteristics. 
Conclusions: AS patients reported good QoL and did not appear to suffer major negative psychological 
impacts. Longer follow-up is required as well as investigation into which patients are predisposed to negative 
impacts and leaving AS prematurely. 
Patient summary: We reviewed the published evidence for quality of life impacts for men with prostate 
cancer being monitored by Active Surveillance (AS). The men who were on AS usually reported good levels 
of well-being and did not appear to suffer major negative psychological impacts. The research findings 
suggest little presence of anxiety and depression and high overall quality of life related to their disease. 
However, there are few long-term studies so more high quality research is needed to make definitive 
recommendations. 
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1. Introduction 
The incidence of prostate cancer (PCa) worldwide is increasing as opportunistic screening becomes 
more widespread and average life expectancy rises [1]. A large randomised controlled trial showed 
disease-specific mortality benefits to population-based prostate cancer screening in Europe 
(ERSPC) [2,3] with less clear results in a similar trial in the USA (PLCO), possibly due to the high 
rates of prostate specific antigen (PSA) testing in their control group [4]. However, both over-
diagnosis and resulting over-treatment are problematic sequelae of prostate cancer screening due to 
the low diagnostic specificity of PSA and prostatic biopsies.  
 
Active Surveillance (AS) is an option for patients with favourable risk, localised PCa, which aims 
to avoid or delay radical treatments without compromising long term disease-specific survival. AS 
involves regular monitoring by multimode imaging, PSA and prostatic biopsies [5-7]. AS has 
existed for around fifteen years worldwide although uptake has generally been modest outside 
established research cohorts such as the PRostate cancer International Active Surveillance (PRIAS) 
study [8]. However, recent prominence of AS in American and European prostate cancer 
management guidelines will potentially further increase utilisation of this approach [9].  
Radical treatment can result in lifetime impacts for patients' quality of life (QoL), including erectile, 
rectal and urinary dysfunctions [10]. AS patients can potentially avoid these consequences of 
radical treatment but may suffer negative psychological effects due to living with an untreated 
cancer and the fear of disease progression [11-13]. If AS patients experience heightened distress 
and anxiety, they are potentially more likely to opt for radical treatment in advance of protocol-
based recommendations [14].  
The need to understand the potential psychological burden of AS was identified during and 
international  AS conference, in February 2014 in Amsterdam. This systematic review aimed to 
evaluate the published evidence on the health-related quality of life (HRQoL) and its related 
psychological dimensions in men undergoing AS to help inform clinical practice and treatment 
decision-making. Previous literature reviews in this area were either non-systematic [13-15] or 
combined HRQoL studies of AS patients with those of passive observation without radical 
intervention (“watchful waiting”, WW) for patients unsuitable for radical treatment [12] or were 
focused on the clinical outcomes of AS [5]. 
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2. Evidence Acquisition 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines [16] with predefined search terms, inclusion/exclusion criteria, data 
collection and analysis processes.  
2.1 Study eligibility criteria. All study designs with quantitative HRQoL data from men with 
localised PCa receiving AS were eligible (without age restriction). This review focused on overall 
HRQoL and on the psychological dimensions related to HRQoL, i.e. anxiety, depression, decisional 
conflict, coping, distress, satisfaction, and mental health as well as other psychological factors 
potentially related to AS as shown in previous qualitative studies (e.g. uncertainty) and measured 
with standardised or validated questionnaires. Studies purely reporting on the physical aspects of 
HRQoL (e.g. urinary or bowel symptoms or erectile function) were ineligible. Studies either with 
men receiving WW, or where it was unclear if they were AS patients were excluded as QoL data for 
men on WW are not comparable to that from men on AS given the palliative aim of WW versus the 
curative intent of AS [9, 17]. Full-text original articles in English were eligible without restriction 
on publication date. If multiple papers originated from one dataset, we included the one with the 
longest follow-up period. 
2.2 Search strategy and study selection. Studies were identified by searching electronic databases 
and scanning reference lists of selected articles. In May 2014, Embase, Medline, Psychinfo, 
Cochrane Central, Web of Science, and PubMed (strategy in Appendix 1) were searched using 
'quality of life', 'active surveillance' and 'prostate cancer' and their relevant synonyms. Reference 
lists were also searched of potentially eligible publications and previous literature reviews of QoL 
and AS [13-15]. Two authors (I.K., L.B.) independently screened all the titles/abstracts and the 
resulting reference list was compiled by a third author (J.A.L.) for full text screening and data 
extraction. Disagreements were resolved by consensus. 
2.3 Data collection. Three authors (J.A.L., I.K., L.B.) extracted data onto a form that was designed 
and piloted on six AS studies for one third of the selected references. Two other authors (L.V., 
R.vdB.) each checked half of the data extraction forms (randomly assigned) against the full-text 
papers. Data extracted included: study design, setting, timing of HRQoL assessments, country, AS 
protocol, outcomes, follow-up duration, study population (clinical, research or population registry), 
HRQoL data collection methods, inclusion/exclusion criteria, risk of bias, standardised/validated 
questionnaires, number of participants, response rates, responder and non-responder characteristics, 
effect estimates for outcomes and rates of leaving AS due to anxiety.   
 
5 
 
3. Evidence synthesis 
The literature search identified 1,157 unique citations (Fig. 1 – flowchart ); 1087 citations were 
excluded as they were reviews, commentaries, abstracts, validation of questionnaires or participants 
were on WW.  Three citations were identified by searches of bibliographies, thus leaving 73 
citations for a full-text screening. Of these, 63 citations were excluded. Major reasons for exclusion 
were that patients did not meet eligibility criteria for AS (n=27), no mental qualify of life data was 
reported (n=9); papers reported on reviews (n=8) or that combined data was reported of men treated 
by various therapies (n=4).. Data extraction from these papers was concordant between the first and 
second reviewers. Table 1 presents the design, sample and key methodological features of the 10 
included studies. 
3.1 Study and AS patients characteristics. Seven of the 10 included AS studies were conducted in 
Europe, two in Northern America and one in Australia (Table 1). Three AS studies reported using 
the PRIAS protocol for monitoring patients, two the UCSF protocol and one the Royal Marsden 
Hospital protocol. The HRQoL assessments were reported between 2006-2014 and all the study 
designs were observational: six cross-sectional and four cohorts with follow-up up to three years in 
one cohort and up to a year in the others. Eight studies reported on QoL assessment at different time 
points after opting for AS; one of the selected studies reported specifically on predictors of QoL and 
one assessed the impact of a life-style change intervention in men on AS. The total number of AS 
patients was 996 ranging from 61-150 men per study (mean 102) with 557 patients who had 
undergone radical prostatectomy as the largest comparator group [21]. Mean age across the 
different studies was 66 years. Four studies used (combinations of) comparison groups of prostate 
cancer patients. These were men undergoing or having undergone active treatment; post radical 
prostatectomy (n=2), radiotherapy (n=4) and hormonal therapy (n=2). One study assessed men’s 
partners and three used population-based data.  
3.2 Outcomes. Fifteen different measures were used to assess the various facets of HRQoL and 
psychological dimensions (Table 2). Global HRQoL indexes were obtained by using the SF-36 [28] 
or SF-12 [29], the EORTC QLQ-C30 [30] and the Quality of Life – Cancer Survivors scale [31]. 
The Functional Assessment for Cancer Therapy scale was also used in one study to assess both 
general and prostate-related HRQoL (FACT-G and FACT-P) [32]. Mental health was measured 
with the SF-36 or SF-12 (four studies) mental health subscale. Two studies measured anxiety and 
depression with the Hospital Anxiety and Depression Scale (HADS) [33] and one with the Patient 
Health Questionnaire [34]; depression was also measured by the CES-D in one study [35]. The tools 
to assess anxiety were also the General Anxiety Disorder Scale [36] and the State Trait Anxiety 
Inventory [37]. Specific PCa-related anxiety was measured with the Memorial Anxiety for Prostate 
Cancer (MAX-PC) scale [38] in three studies. One study assessed stress levels by using the 
Perceived Stress Scale [39, another decisional conflict [40] and another coping (Mini-Mental 
Adjustment to Cancer Scale, (Mini-MAC) [41].  One study used the Distress Thermometer (DT) 
[42] which specifically measures psychological burden in oncology patients.  
Overall HRQoL.  High overall HRQoL scores were reported in seven AS studies, thus indicating 
good quality of life. No major differences were observed between the HRQoL scores of AS patients 
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and their comparison groups [19, 21, 23, 25, 26]. There were also no major changes in HRQoL after 
9 or 12 months on AS in two PRIAS cohorts [24, 26].Finnish PRIAS men also reported higher 
scores than a population sample at baseline and follow-up assessments, which the authors suggested 
may result from men with favourable psychological characteristics choosing AS. Vanagas et al. [25] 
highlighted that men on AS reported significantly better HRQoL than men who underwent radical 
treatment in both functional and symptom scales although these results by treatment group were not 
sub-divided by tumour stage.   
 
Bellardita et al. [18] found that high levels of HRQoL were predicted by a patient having consulted 
several physicians about the choice of AS, by the presence of a partner, and a diagnostic biopsy 
with more than 18 core specimens. Daubenmier et al. [20], comparing two groups of patients 
undergoing or not a lifestyle intervention, pointed out that participants of both groups reported high 
HRQoL at baseline; interestingly, those who improved their lifestyle, also enhanced their HRQoL 
further. 
 
Mental health. Four studies reported on mental health by using the SF-36 mental health index and 
found that patients were doing well [20, 23, 24, 26]. Thong et al. found that mean mental health 
score of men on AS was about 80 and was similar to the mean score for a normative population, 
matched for age and sex, and up to ten years after diagnosis. In the same study it was highlighted 
that 17 AS patients with subjective perception of disease progression showed worse mental health 
scores than AS patients without such a perception of disease progression. In the Dutch PRIAS 
cohort the baseline mental health score was associated with 9-month follow-up scores [24] and 
there were no changes over 9 or 12 months follow-up in either of the two PRIAS cohorts [24, 26]. 
In summary, these findings do not seem to justify the concern that “living with untreated cancer” 
negatively impacts on the mental health of patients on AS. Longer term follow-up will be essential, 
however, to elucidate whether there may be later subtle erosion of patients’ mental health and 
wellbeing over time on AS. 
Anxiety. There was a low frequency of general and disease-specific anxiety in all five AS studies 
that assessed anxiety (usually in the range of 4-15%) [19, 21, 22, 24, 27]. Two studies also 
highlighted that anxiety scores of AS patients were comparable to those of radical prostatectomy 
patients [19, 21]. Punnen et al. [21] compared a group of patients managed with AS with another 
group of men who underwent RP, finding that in both samples moderate to severe levels of anxiety 
were reported by less than 5%, and levels of mild anxiety ranged from 4% to 16%. Burnet et al. [19] 
highlighted that anxiety scores in patients who chose AS did not differ from those of patients who 
were being treated for PCa or were followed-up after radical treatment. In particular, authors 
noticed that younger men were more anxious than older men, and the longer the time since 
diagnosis the more anxious the men became. The general and PCa-specific anxiety declined slightly 
(<0.5 of a standard deviation) over 9 months in Dutch PRIAS patients but this was not clinically 
significant [24]. The fear of disease progression declined significantly over nine months (mean 
score 4.2 to 3.5, p= 0.005) in the Dutch PRIAS cohort, which warrants further exploration in other 
AS cohorts. Furthermore, baseline scores were predictive of scores at nine months in this PRIAS 
cohort.  
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Seiler et al. [22] investigated the level of anxiety not only in patients with PCa, but in their wives as 
well, arguing that the partners could suffer more from the diagnosis than the men themselves.  As 
predicted, the partners’ anxiety scores indicated higher levels of concern than their husbands: 
overall, among men, the domain for PSA anxiety was rated very low (it should be noticed that in 
this cohort men do not dread PSA testing, despite having to undergo it regularly).  More generally, 
since the values scored by both men and their partners were within the normal range of the general 
population, the authors concluded that anxiety for these individuals was not clinically relevant. 
Similarly, Wilcox et al. [27] underlined that the level of anxiety relating specifically to prostate 
cancer, in a cohort of Australian patients on AS, was below the defined threshold of clinical 
relevance. 
Depression. Depression is an established response to a diagnosis of cancer which is unrelated to 
disease stage or severity [43]. Four studies showed that few AS patients reported depressive 
symptoms [19, 21, 22, 24]. No major changes in depressive symptoms were observed over the first 
nine months of AS in the Dutch cohort [24]. There were no major differences in depressive 
symptoms between AS and radical prostatectomy patients in the American study [21] nor in the 
Swiss cohort [22] with men’s partners or population data. For instance, less than 5% of men in the 
UCSF cohort reported moderate-to-severe depression [21]. Burnet et al. [19], comparing three 
groups of patients (on AS; currently undergoing radical treatment; on follow-up after radical 
treatment), found that the extent of reported depression was associated with a longer interval since 
diagnosis, but not with being on AS.  
Decisional conflict. The decisional conflict scale aims to elicit patients' uncertainty in making a 
health-related decision; the factors contributing to the uncertainty; and patients' perceived effective 
decision making. Van den Bergh et al. [24] found that the extent of reported decisional conflict was 
associated with shared decision making (large perceived physician role) and emotional insecurity. 
Considering the score of decisional conflict over time, authors highlighted that it appeared quite 
stable between the time of diagnosis (t1) and 9 months (t2) after diagnosis (only few men who 
scored within the normal range at t1 then exceeded the clinical threshold at t2). In a previous study 
on the same cohort, the same authors reported that men who elected AS in their cohort reported less 
decisional conflict than a cohort of American patients with localized PCa who had decided on their 
treatment (mostly radical prostatectomy) [44].  
3.3 Predictors of QoL. HRQoL was predicted by baseline socio-demographic, clinical or other 
characteristics in two AS studies [18, 24]. In one study, [24] greater decisional conflict (linked to a 
higher perceived physician role in treatment decision-making) or a higher score in emotional 
instability predicted increased anxiety and distress at nine months whilst better physical health was 
associated with lower scores. In patients within their first 10 months of AS, having a partner, 
multiple physicians during AS selection and an extended diagnostic biopsy (> 18 cores) decreased 
the risk of experiencing poor QoL [18]. Additionally, AS patients with good coping or adjustment 
to cancer scores (i.e. fighting spirit, anxious preoccupation and helplessness/hopelessness) had 
higher QoL scores, whereas low coping scores were associated with the time taken between 
diagnosis and commencing AS. 
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3.4 Intervention studies. One intervention trial aimed to improve eating habits and physical 
exercise levels of AS patients [20]. There were no differences in HRQoL between the randomised 
groups from baseline to 12-months follow-up. It was also noted that some control group AS patients 
pursued lifestyle changes. Men participating in the ProtecT randomised trial of active monitoring (a 
surveillance strategy), radical prostatectomy and radiotherapy generally made healthy dietary 
changes following diagnosis (e.g. less red meat) with greater changes made by those on active 
monitoring [45].  
3.5 Limitations of QoL AS studies. Summarising the 10 studies gave novel insights into the QoL of 
AS patients. However, none of the AS studies had a randomised comparison group, some were 
rather small or had limited follow-up. Most studies lacked an appropriate control group making it 
difficult to disaggregate the psychological impacts for AS patients of  “living with untreated 
disease” and the general burden for cancer survivors [46, 47]. Measurement of the HRQoL across a 
wider demographic range of AS patients could enhance the generalisability of these results given 
that most studies did not report the ethnicity or socio-demographics of their patients. All 10 studies 
lacked assessment of men’s HRQoL before commencing on AS which may have introduced a self-
selection bias and few studies made analytic adjustments for age or other demographic variables or 
missing data. Only two studies included men who left AS. Questionnaire performance metrics were 
poorly reported, e.g. the reliability, responsiveness and sensitivity of measures, thus making it 
difficult to assess the quality of findings. Moreover, the statistical significance of some HRQoL 
scores needs to be translated into quality of life differences that are meaningful to both patients and 
clinicians.  
3.6 Limitations of the systematic review. Some relevant studies may have been omitted from this 
review as there are at least seven published AS cohorts worldwide and yet we only identified 
HRQoL results from three institutions participating in PRIAS, the Royal Marsden Hospital and 
UCSF cohorts. This may reflect the absence of HRQoL results from the other AS cohorts as 
HRQoL research into AS is relatively recent but it is unlikely to be a language bias as clinical data 
from theses cohorts have been published in English. We excluded interview-based studies [48] 
which can give useful insights into men’s perspectives as they could not be combined with 
quantitative data and also studies where it was not possible to determine if patients were receiving 
passive observation (WW) or AS. Finally, the QoL outcomes could not be combined in a meta-
analysis as there were no universal measures across the 10 studies so we were also unable to assess 
the overall impact of different AS protocols on HRQoL, including triggers for radical treatment. 
3.7 Future directions. Understanding the complexity of the HRQoL of AS patients requires 
multidimensional assessment, including interpretation of QoL scores for clinical practice and 
patients. Longitudinal assessment of HRQoL with a core set of QoL measures in all AS cohorts to 
inform future meta-analyses would be advantageous with the PRIAS studies currently increasing 
the evidence base most strongly. Further investigation of the characteristics of men commencing AS 
that may predict subsequent psychological harms and their potential for leaving AS prematurely 
would be highly beneficial, including how patients interpret AS tools (e.g. PSA, imaging and 
biopsy results) which may also impact negatively their QoL and their decision to remain on AS. 
The partners of AS patients [22] were shown to experience slightly higher depressive symptoms 
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(but not anxiety) and lower general health status, role and emotional functioning than the men. 
Partners and other family members may be influential regarding initiation and maintenance on AS 
so further empirical data on the potentially mutual emotional influences and supportive role of 
partners/family could be instructive. Finally, the ProtecT randomised trial of prostate cancer 
treatments with HRQoL, anxiety and depression measured pre-diagnosis and annually for at least 10 
years in active monitoring patients will report in 2016 [49] which should provide detailed insights 
both clinically and for AS patients on the immediate and long term psychological impacts of active 
surveillance. 
4. Conclusions  
Controversy exists around the nature and extent of the burden of living with untreated PCa for AS 
patients. This systematic review based on around 1,000 AS patients in 10 studies indicated no major 
perturbations to their HRQol and psychological wellbeing in the first few years. These findings are, 
to our knowledge, the first systematic review to focus entirely on the HRQoL of AS patients. 
Limitations of the review included a potential self-selection bias as no studies were randomised, 
comparator groups were used infrequently and follow-up was limited. Nevertheless, men on AS 
generally reported high levels of overall HRQoL in the short term, which was comparable to men 
who underwent radical treatments. Anxiety, depression and distress also seemed not to represent a 
major burden for most AS patients in their first few years. However, assessment of anxiety, 
depression and distress should nevertheless be considered for AS patients and support offered 
where psychological distress is severe and unremitting over time [50] or arises during AS. Further 
research should aim to provide robust high quality long term data that can inform clinical practice, 
patients and the patient-physician decision making process. 
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Appendix 1 Complete Search strategy  
Question:  How does active surveillance affect quality of life of men with prostate cancer? 
Date:   22 May 2014 
Databases: Embase, Medline (Ovid-SP), Cochrane Central (trials), PsycInfo, Web of Science, PubMed 
publisher (recent) 
 
Results (after deduplication): 
Total: 1812 (1157) 
 
Embase(Embase plus Medline): 867 (864) 
('Prostate Cancer'/exp OR (prostat* NEAR/6 (cancer* OR carcinom* OR tumor* OR tumour* OR 
neoplas* OR adenocarcino*)):ab,ti) AND ('Quality of life'/de OR 'Quality adjusted life year'/de OR 
'Emotion'/exp OR 'Depression'/de OR 'Anxiety Disorder'/de OR 'Distress syndrome'/de OR 'Mixed 
anxiety and depression'/de OR 'Reactive depression'/de OR 'Stress'/exp OR 'Conflict'/de OR 
'Psychological well being'/de OR 'Psychological aspect'/de OR 'Coping behavior'/de OR 'Satisfaction'/de 
OR 'Patient satisfaction'/de OR ((Quality NEAR/4 (life OR living)) OR QAL OR QALY OR HRQOL OR QOL OR 
emotion*OR depress* OR anxiet* OR anxious OR fear*OR stress* OR distress* OR resilien* OR nervous* 
OR nervos* OR worry* OR mood OR happiness OR happy OR unhapp* OR wellbeing OR well being* OR 
coping OR satisfaction* OR conflict OR conflicts OR uncertain* OR psycholog* OR psychosoci* OR 
(psycho NEXT/1 soci*)):ab,ti) AND ('Disease surveillance'/de OR 'Patient monitoring'/exp OR 'Watchful 
waiting'/de OR (((active OR patient OR observation*) NEAR/3 (surveillance OR monitoring)) OR watchful 
OR (expectant NEXT/1 manag*)):ab,ti) NOT ([animals]/lim NOT [humans]/lim) 
 
Medline OVID-SP: 373 (82) 
(exp "Prostatic Neoplasms"/ OR (prostat* ADJ6 (cancer* OR carcinom* OR tumor* OR tumour* OR 
neoplas* OR adenocarcino*)).ab,ti.) AND ("Quality of life"/ OR "Quality adjusted life years"/ OR exp 
"Emotions"/ OR "Depression"/ OR "Anxiety Disorders"/ OR "Depressive Disorder"/ OR "Behavioral 
symptoms"/de OR "Mental Fatigue"/de OR "Stress, Psychological"/ OR "Conflict (Psychology)"/ OR 
"Personal Satisfaction"/ OR exp "Patient Satisfaction"/ OR exp "Adaptation, Psychological"/ OR 
"psychology".xs. OR ((quality ADJ4 (life OR living)) OR QAL OR QALY OR HRQOL OR QOL OR emotion* OR 
feeling* OR depress* OR anxiet* OR anxious OR fear*OR stress* OR distress* OR resilien* OR nervous* 
OR nervos* OR worry* OR mood OR happiness OR happy OR unhapp* OR wellbeing OR well being* OR 
coping OR satisfaction* OR conflict OR conflicts OR uncertain* OR psycholog* OR psychosoci* OR 
(psycho ADJ soci*)).ab,ti.) AND ("Disease surveillance"/ OR "Patient monitoring"/ OR "Watchful 
waiting"/ OR (((active OR patient OR observation*) ADJ3 (surveillance OR monitoring)) OR watchful OR 
(expectant ADJ manag*)).ab,ti.) NOT (animals NOT humans).sh. 
 
PsycInfo: 49 (22) 
((exp "Neoplasms"/ AND ("Prostate"/ OR prostat*.ab,ti.)) OR (prostat* ADJ6 (cancer* OR carcinom* OR 
tumor* OR tumour* OR neoplas* OR adenocarcino*)).ab,ti.) AND (exp "Quality of life"/ OR exp 
"Emotions"/ OR "Emotional Stability"/ OR "Emotional Instability"/ OR "Depression (Emotion)"/ OR exp 
"Anxiety"/ OR exp "Behavior"/ OR "Psychological Stress"/ OR "Resilience (Psychological)"/ OR 
"Psychological Endurance"/ OR "Uncertainty"/ OR "Life Satisfaction"/ OR "Well being"/ OR "Mental 
Health"/ OR "Adjustment"/ OR "Adjustment Disorders"/ OR ((quality ADJ4 (life OR living)) OR QAL OR 
QALY OR HRQOL OR QOL OR emotion* OR feeling* OR depress* OR anxiet* OR anxious OR fear*OR 
stress* OR distress* OR resilien* OR nervous* OR nervos* OR worry* OR mood OR happiness OR happy 
OR unhapp* OR wellbeing OR well being* OR coping OR satisfaction* OR conflict OR conflicts OR 
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uncertain* OR psycholog* OR psychosoci* OR (psycho ADJ soci*)).ab,ti.) AND (exp "Attention"/ OR 
"Disease management"/ OR (((active OR patient OR observation*) ADJ3 (surveillance OR monitoring)) 
OR watchful OR (expectant ADJ manag*)).ab,ti.) 
 
Cochrane Central (trials): 35 (5) 
((prostat* NEAR/6 (cancer* OR carcinom* OR tumor* OR tumour* OR neoplas* OR 
adenocarcino*)):ab,ti) AND (((quality NEAR/4 (life OR living)) OR QAL OR QALY OR HRQOL OR QOL OR 
emotion*OR depress* OR anxiet* OR anxious OR fear*OR stress* OR distress* OR resilien* OR nervous* 
OR nervos* OR worry* OR mood OR happiness OR happy OR unhapp* OR wellbeing OR well being* OR 
coping OR satisfaction* OR conflict OR conflicts OR uncertain* OR psycholog* OR psychosoci* OR 
(psycho NEXT/1 soci*)):ab,ti) AND ((((active OR patient OR observation*) NEAR/3 (surveillance OR 
monitoring)) OR watchful OR (expectant NEXT/1 manag*)):ab,ti) 
 
Web of Science: 472 (172) 
TS=(((prostat* NEAR/6 (cancer* OR carcinom* OR tumor* OR tumour* OR neoplas* OR 
adenocarcino*))) AND (((quality NEAR/4 (life OR living)) OR QAL OR QALY OR HRQOL OR QOL OR 
emotion*OR depress* OR anxiet* OR anxious OR fear*OR stress* OR distress* OR resilien* OR nervous* 
OR nervos* OR worry* OR mood OR happiness OR happy OR unhapp* OR wellbeing OR well being* OR 
coping OR satisfaction* OR conflict OR conflicts OR uncertain* OR psycholog* OR psychosoci* OR 
(psycho NEXT/1 soci*))) AND ((((active OR patient OR observation*) NEAR/3 (surveillance OR 
monitoring)) OR watchful OR (expectant NEXT/1 manag*))) NOT ((animal* OR mice OR mouse OR pig OR 
pigs OR rats) NOT human*)) 
 
PubMed recent (as supplied by publisher): 16 (12) 
(prostat*[tiab] AND (cancer*[tiab] OR carcinom*[tiab] OR tumor*[tiab] OR tumour*[tiab] OR 
neoplas*[tiab] OR adenocarcino*[tiab])) AND ((Quality[tiab] AND (life[tiab] OR living[tiab])) OR QAL[tiab] 
OR QALY[tiab] OR HRQOL[tiab] OR QOL[tiab] OR emotion*[tiab]OR depress*[tiab] OR anxiet*[tiab] OR 
anxious[tiab] OR fear*[tiab]OR stress*[tiab] OR distress*[tiab] OR resilien*[tiab] OR nervous*[tiab] OR 
nervos*[tiab] OR worry*[tiab] OR mood[tiab] OR happiness[tiab] OR happy[tiab] OR unhapp*[tiab] OR 
wellbeing[tiab] OR well being*[tiab] OR coping[tiab] OR satisfaction*[tiab] OR conflict[tiab] OR 
conflicts[tiab] OR uncertain*[tiab] OR psycholog*[tiab] OR psychosoci*[tiab] OR psycho soci*[tiab]) AND 
(((active[tiab] OR patient[tiab] OR observation*[tiab]) AND (surveillance[tiab] OR monitoring[tiab])) OR 
watchful[tiab] OR expectant manag*[tiab]) AND publisher[sb] 
 
Figure 1. PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
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patients did not meet eligibility criteria for 
AS (n=27); no mental qualify of life data was 
reported (n=9); papers were review studies 
(n=8) or abstracts (n=6); reported only data 
of various therapies combined (n=4); were 
non-English (n=2); duplicates (n=2) or 
reported on same patient population  as 
included paper (n=2); reported no patients’ 
characteristics (n=1); had a response rate of 
<1% (n=1) or only 5 participants (n=1) 
Studies included in 
qualitative synthesis 
(n = 10) 
Figure 1 Flowchart
Active Surveillance 
study (AS), 
publication date 
QoL study  
design 
Assessment 
period 
AS protocol 
Setting  
Country 
Total sample/response 
rate 
N of AS men 
(mean age in 
years)  
N of control men 
(mean age in years); 
Population data (PD) 
Bellardita, 2013 [18] Cohort 2007-2012 PRIAS 
Research 
Italy 
154/67% 
154 (67) None 
Burnet, 2007 [19] Cross-
sectional 
NR Royal Marsden Hospital 
Research  
United Kingdom 
493/72% (24 excluded) 
 100 (67) Radical treatment (=HT or 
RT; 81); or post-radical 
treatment (148) 
Daubenmeier, 2006 
[20] 
Cross-
sectional 
NR UCSF 
Research  
USA 
93/NR 
44 men on AS 
assigned to a 
lifestyle 
intervention (65 ) 
49 men on AS assigned to 
usual- 
care control group (66) 
Punnen, 2013 [21] Cohort 2007-2010 UCSF 
Clinical 
USA 
864/77% 
122 newly 
diagnosed, no 
active treatment 
>6m post-diagnosis 
(61) 
557 post-RP (60) 
Seiler, 2012 [22] Cross-
sectional 
2010 NR 
Clinical  
Switzerland 
282/47% 
133 with Epstein 
eligibility criteria 
(69) 
133 partners of AS men 
PD 
Thong, 2009 [23] Cross-
sectional 
2004 Not protocol-based 
Clinical 
The Netherlands 
128 from registry data 
eligible for AS /55% 
71 (76) 71 men post-RT (76) 
patients of similar age and 
comparable disease 
characteristics 
PD 
Table 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Overview of Active Surveillance for prostate cancer QoL studies 
AS = Active Surveillance; HT = hormone therapy,  PRIAS= PRostate cancer International Active Surveillance; PCa = prostate cancer;;  RM=Royal 
Marsden Hospital; RP = radical prostatectomy, RT = radiotherapy; CH = chemiotherapy; UCSF = University of California San Francisco; NR = not 
reported; PD = population data. 
 
van den Bergh, 2010 
[24] 
Cohort 2007-2008 PRIAS 
Research  
The Netherlands 
150/86% 
129 (65) None 
Vanagas, 2013 [25] Cross-
sectional 
2010-2011 NR 
Clinical  
Lithuania 
650/79% 
61 (NR) 92 post-RP, 73 post-RT  
and 187 on HT + 88 
including CH and 
combined therapy (NR) 
Vasarainen, 2012 [26] Cohort 2006 PRIAS 
Research  
Finland 
124/85% 
105  (64) None 
PD 
Wilcox, 2014 [27] Cross-
sectional 
2013 NR 
Clinical  
Australia 
61/77% 
47 (NR) None 
Active 
Surveillance (AS) 
study, year of 
publication 
QoL outcomes  QoL standardised 
measures  
Baseline assessment 
(T1);  months of 
follow-up (T2, T3) 
Key findings Quality of life on AS 
Bellardita, 2013 
[18] 
HRQoL, coping 
 
FACT-P, FACT-G, 
Mini-MAC 
T1 = AS enrolment;  
T2 = 10 
QoL predicted by lack of a partner; 
recent diagnosis, influence of 
physicians on decision, number of 
biopsy cores; impaired mental 
health at enrolment  
Only a minority of patients 
reported low levels of QoL 
which could be predicted by 
patients’ characteristics at 
baseline 
Burnet, 2007 [19] Anxiety, 
depression 
HADS T1 = AS enrolment; 
during or post-
treatment for control 
subjects 
33% of participants had high 
anxiety (mean 6.14 SD 3.76) and 
11% met criteria for depression 
(mean 3.68 SD 3.07);  threshold ≥ 8 
based on normative sample 
No  major treatment  effects on 
anxiety or depression 
Daubenmeier, 
2006 [20] 
HRQoL (MH 
index), stress 
SF-36, Perceived Stress 
Scale 
T1 = post-
randomisation before 
intervention;  
T2 = 12 
Mental health scores did not change 
between T1 and T2 in both lifestyle 
change and control group (mean 51 
and 56, respectively); Perceived 
stress scores remained about 1 in 
both groups at T1 and T2. 
Men in the intervention group 
improved their life-style but no 
significant differences between 
groups were found from 
baseline to 12 m follow-up as 
far as QoL; lifestyle index 
scores were significantly related 
to scores on SF-36 subscales 
Punnen, 2013 [21] Anxiety, 
depression, 
distress 
Patient Health 
Questionnaire; General 
Anxiety Disorder 
Scale; Distress 
Thermometer 
T1= before RP or 
<6m  from diagnosis 
for AS; T2= <1 yr 
after T1; T3= 
between1 and 3yrs 
post-T1 
Rates of moderate-to-severe 
depression were <5% in both 
groups; mild depression was 
reported by 3% to 12% of 
participants; anxiety was moderate 
to severe in <5% of men, mild in 
4% to 16% in both groups; ≥ 4% of 
men reported high distress scores. 
No significant differences 
between AS and RP in severity 
of anxiety and/or depression nor 
in the proportion of men with 
high distress scores. 
Seiler, 2012 [22] HRQoL, general 
and PCa- anxiety, 
depression 
HADS, MAX-PC, 
EORTC QLQ-C30 
T1 = median of 45 m 
from diagnosis, 17, 
32, 59 or 136 months 
Patients’ HRQoL scores were 
similar or higher to normative 
population scores; MAX-PC scores 
were lower than the reference value 
for 91.7%;  
85.7% scored below the reference 
value of the HADS domains.  
No major overall or disease-
specific anxiety or distress at 4 
times post-diagnosis for men; 
possibly more impact for 
partners  
Table 2
Thong, 2010 [23] HRQoL ( mental 
health) 
SF-36, Quality of Life -
Cancer Survivors 
T1 =  mean of 8 yrs 
on AS  
No significant differences  between 
AS, RT groups and PD 
AS men with disease progression  
had worse  mental and emotional 
health 
No major impacts on QoL for 
men up to 10 y on AS compared 
with RT. 
Negative impacts for those with 
disease progression on AS. 
van den Bergh, 
2010 [24] 
HRQoL (MH 
index), anxiety, 
depression, 
decisional conflict 
DCS, CES-D, STAI-6, 
MAX-PC, SF-12 
T1 = <6 m from 
diagnosis;  
T2 = 9 
Anxiety scores decreased   as  STAI 
(p = 0.016) and MAX-PC fear of 
progression  (p= 0.005)  
with decreases > 0.5 SD (not 
clinically relevant); the incidence of 
men scoring above clinical 
thresholds at t1 and t2 was 20% and 
25% for DCS;  6% and 8% for 
CES-D; 17% and 12% for STAI-6; 
and 7% and 9% for MAX-PC, 
respectively.  
Anxiety and distress were 
clinically stable over 9 months. 
Baseline characteristics partly 
predicted distress and anxiety 
during follow-up 
Vanagas, 2013 [25] HRQoL,  EORTC QLQ-C30 NR Mean scores for EORTC QLQ-C30 
functional scales range was 73-90 
for men on AS; AS men had 
highest emotional, role and social 
functioning scores of PCa 
treatments 
Favourable QoL profile for AS 
patients compared with radical 
treatment or HT 
Vasarainen, 2012 
[26] 
HRQoL (MH 
index) 
SF-36 T1 = start of AS; T2 
= 12 
SF36 scores ranged from 65 
(general health index) to 91 (social 
functioning) at T1 and from 
remained stable at T2; MH index 
mean score was 81 at both times. 
No differences were found 
between baseline and follow-up 
assessment; men on AS who had 
better quality of life than the 
reference group (normative 
population). 
Wilcox, 2014 [27]  PCa-related 
anxiety 
MAX-PC NR The mean overall MAX-PC was 
15.5 (95% CI 13.4–17.6) with 
subscale results of 7.4/33 for 
general anxiety (95% CI 5.5–9.3), 
0.8/9 for PSA specific anxiety 
(95% CI 0.3–1.3) and 7.3/12 for 
fear of recurrence (95% CI 6.5–
8.2). 
No disease specific anxiety 
reported in Australian men 
 
Table 2. QoL measurement, outcomes and key findings from AS for prostate cancer studies.  
 
QoL = quality of life; HRQoL =  health-related quality of life; MH = mental health; FACT-P = Functional Assessment of Cancer Therapy – Prostate version; 
FACT-G = Functional Assessment of Cancer Therapy – General; Mini-MAC = Mini-Mental Adjustment to Cancer;; HADS = Hospital Anxiety and Depression 
Scale; SF-36 = Short form 36; MAX-PC = Memorial Anxiety scale for Prostate Cancer; EORTC QLQ-C30 =  European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire 30; DCS = Decisional Conflict Scale; CES-D = Center for Epidemiologic Studies Depression Scale; STAI-6 = 
State-Trait Anxiety Inventory; SF-12 = Short Form 12; PD = Population Data; PCa = prostate cancer; HT = hormone therapy; RP = radical prostatectomy; RT = 
radiotherapy;  m = months; NR = not reported. 
 
 
 
Take home message  
Active surveillance for prostate cancer appears to have no major impacts on health-related quality of life and 
psychological wellbeing in the first few years. However, there is no randomised evidence and results are 
limited over the longer term.  
 
*Take Home Message
